» Articles » PMID: 32295103

Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Apr 17
PMID 32295103
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Sphingolipids represent a class of bioactive lipids that modulate the biophysical properties of biological membranes and play a critical role in cell signal transduction. Multiple studies have demonstrated that sphingolipids control crucial cellular functions such as the cell cycle, senescence, autophagy, apoptosis, cell migration, and inflammation. Sphingolipid metabolism is highly compartmentalized within the subcellular locations. However, the majority of steps of sphingolipids metabolism occur in lysosomes. Altered sphingolipid metabolism with an accumulation of undigested substrates in lysosomes due to lysosomal enzyme deficiency is linked to lysosomal storage disorders (LSD). Trapping of sphingolipids and their metabolites in the lysosomes inhibits lipid recycling, which has a direct effect on the lipid composition of cellular membranes, including the inner mitochondrial membrane. Additionally, lysosomes are not only the house of digestive enzymes, but are also responsible for trafficking organelles, sensing nutrients, and repairing mitochondria. However, lysosomal abnormalities lead to alteration of autophagy and disturb the energy balance and mitochondrial function. In this review, an overview of mitochondrial function in cells with altered sphingolipid metabolism will be discussed focusing on the two most common sphingolipid disorders, Gaucher and Fabry diseases. The review highlights the status of mitochondrial energy metabolism and the regulation of mitochondria-autophagy-lysosome crosstalk.

Citing Articles

Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy.

Ivanova M, Dao J, Friedman A, Kasaci N, Goker-Alpan O Cells. 2025; 14(5).

PMID: 40072051 PMC: 11899294. DOI: 10.3390/cells14050322.


Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice.

Mignani R, Biagini E, Cianci V, Pieruzzi F, Pisani A, Tuttolomondo A Adv Ther. 2024; 42(2):597-635.

PMID: 39636569 PMC: 11787255. DOI: 10.1007/s12325-024-03041-2.


Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models.

Huang S, Abutaleb K, Mishra S Biomolecules. 2024; 14(10).

PMID: 39456198 PMC: 11506000. DOI: 10.3390/biom14101265.


2024 Update of the TSOC Expert Consensus of Fabry Disease.

Hung C, Wu Y, Kuo L, Sung K, Lin H, Chang W Acta Cardiol Sin. 2024; 40(5):544-568.

PMID: 39308653 PMC: 11413953. DOI: 10.6515/ACS.202409_40(5).20240731A.


The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies.

Pieroni M, Ciabatti M, Graziani F, Camporeale A, Saletti E, Lillo R Rev Cardiovasc Med. 2024; 23(6):196.

PMID: 39077177 PMC: 11273771. DOI: 10.31083/j.rcm2306196.


References
1.
Sun Y, Liou B, Ran H, Skelton M, Williams M, Vorhees C . Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010; 19(6):1088-97. PMC: 2830832. DOI: 10.1093/hmg/ddp580. View

2.
Batta G, Soltesz L, Kovacs T, Bozo T, Meszar Z, Kellermayer M . Alterations in the properties of the cell membrane due to glycosphingolipid accumulation in a model of Gaucher disease. Sci Rep. 2018; 8(1):157. PMC: 5760709. DOI: 10.1038/s41598-017-18405-8. View

3.
Magalhaes J, Gegg M, Migdalska-Richards A, Schapira A . Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018; 8(1):1385. PMC: 5780491. DOI: 10.1038/s41598-018-19479-8. View

4.
Lonser R, Schiffman R, Robison R, Butman J, Quezado Z, Walker M . Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology. 2006; 68(4):254-61. DOI: 10.1212/01.wnl.0000247744.10990.e6. View

5.
Maor G, Rencus-Lazar S, Filocamo M, Steller H, Segal D, Horowitz M . Unfolded protein response in Gaucher disease: from human to Drosophila. Orphanet J Rare Dis. 2013; 8:140. PMC: 3819655. DOI: 10.1186/1750-1172-8-140. View